Arcutis Biotherapeutics Inc. (ARQT), on Monday, announced that its phase 2 study evaluating ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with atopic dermatitis has yielded positive topline results.
In the phase 2 study, dubbed INTEGUMENT-INFANT, which enrolled 101 infants, 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4. Moreover, the product was well tolerated and demonstrated a safety profile consistent with previous studies, with no new safety signals identified through 4 weeks of treatment.
Zoryve cream, 0.05%, received FDA approval for the topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age as recently as last October.
The company expects to file a supplemental New Drug Application (sNDA) to extend the use of ZORYVE cream 0.05% to patients aged 3 months to less than 24 months next quarter (Q2 2026).
ARQT closed Friday's (Jan.30, 2026) trading at $25.37, down 1.40%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.